Evaluation of in vitro activity of the class i PI3K inhibitor buparlisib (BKM120) in pediatric bone and soft tissue sarcomas

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Anderson, Jennifer L ^a   Park, Ann ^a   Akiyama, Ryan ^a   Tap, William D ^b,c   Denny, Christopher T ^a,d   Federman, Noah ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPARLISIB; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE; NVP AEW 541; PICTILISIB; PROTEIN KINASE B; RAPAMYCIN; TRAMETINIB; AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MORPHOLINE DERIVATIVE; MULTIPROTEIN COMPLEX; NVP-AEW541; NVP-BKM120; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PYRIDONE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRIMIDINONE DERIVATIVE; PYRROLE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANCHORAGE INDEPENDENT GROWTH; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EWING SARCOMA; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INCUBATION TIME; OSTEOSARCOMA; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECTS; METABOLISM; MUTATION; PHOSPHORYLATION; SARCOMA; TUMOR CELL LINE;

AMINOPYRIDINES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MORPHOLINES; MULTIPROTEIN COMPLEXES; MUTATION; OSTEOSARCOMA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; PYRIDONES; PYRIMIDINES; PYRIMIDINONES; PYRROLES; SARCOMA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84946925388     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133610     Document Type: Article

References (35)

1. Anderson JL, Denny CT, Tap WD, Federman N. Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities. Pediatr Res. 2012; 72(2):112-21. doi: 10.1038/pr.2012. 54 PMID: 22546864
2. Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, et al. Preliminary efficacy of the antiinsulin- like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol. 2011; 29(34):4534-40. doi: 10.1200/JCO.2010.33.0670 PMID: 22025154
3. Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol. 2011; 29(34):4541-7. doi: 10.1200/JCO.2010.34.0000 PMID: 22025149
4. Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, et al. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer. 2014; 120 (16):2448-56. doi: 10.1002/cncr.28728 PMID: 24797726
5. Schoffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, et al. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer. 2013; 49 (15):3219-28.
6. Tap WD, Demetri G, Barnette P, Desai J, Kavan P, Tozer R, et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol. 2012; 30(15):1849-56. doi: 10.1200/ JCO.2011.37.2359 PMID: 22508822
7. Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X, et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res. 2008; 68(19):8039-48. doi: 10.1158/0008-5472.CAN-08- 1712 PMID: 18829562
8. Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, Astolfi A, et al. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene. 2011; 30(24):2730-40. doi: 10.1038/onc.2010.640 PMID: 21278796
9. Subbiah V, Naing A, Brown RE, Chen H, Doyle L, LoRusso P, et al. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/ resistance signatures. PLoS One. 2011; 6(4):e18424. doi: 10.1371/journal.pone.0018424 PMID: 21494688
10. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006; 66(3):1500-8. doi: 10.1158/0008- 5472.CAN-05-2925 PMID: 16452206
11. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007; 26(13):1932-40. doi: 10.1038/sj. onc.1209990 PMID: 17001314
12. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005; 4(12):988-1004. doi: 10.1038/nrd1902 PMID: 16341064
13. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9(8):550-62. doi: 10.1038/nrc2664 PMID: 19629070
14. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014; 13(2):140-56. doi: 10.1038/nrd4204 PMID: 24481312
15. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012; 30(3):282-90. doi: 10.1200/JCO.2011.36.1360 PMID: 22162589
16. Rodon J, Brana I, Siu LL, De Jonge MJ, Homji N, Mills D, et al. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2014; 32(4):670-81. doi: 10.1007/s10637-014-0082-9 PMID: 24652201
17. Massacesi C, di Tomaso E, Fretault N, Hirawat S. Challenges in the clinical development of PI3K inhibitors. Ann N Y Acad Sci. 2013; 1280:19-23. doi: 10.1111/nyas.12060 PMID: 23551097
18. Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014; 123(22):3390-7. doi: 10.1182/blood-2013-11-535047 PMID: 24615777
19. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370(11):997-1007. doi: 10.1056/ NEJMoa1315226 PMID: 24450857
20. Mathews Griner LA, Guha R, Shinn P, Young RM, Keller JM, Liu D, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A. 2014; 111(6):2349-54. doi: 10.1073/pnas.1311846111 PMID: 24469833
21. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 2012; 11 (2):317-28. doi: 10.1158/1535-7163.MCT-11-0474 PMID: 22188813
22. Anderson JL, Titz B, Akiyama R, Komisopoulou E, Park A, Tap WD, et al. Phosphoproteomic profiling reveals IL6-mediated paracrine signaling within the Ewing sarcoma family of tumors. Molecular cancer research: MCR. 2014; 12(12):1740-54. doi: 10.1158/1541-7786.MCR-14-0159 PMID: 25092916
23. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic acids research. 2015; 43(Database issue):D805-11. doi: 10.1093/nar/gku1075 PMID: 25355519
24. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55. PMID: 6382953
25. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B, et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell. 2007; 129(5):957-68. doi: 10.1016/j.cell.2007.03.051 PMID: 17540175
26. Brachmann SM, Kleylein-Sohn J, Gaulis S, Kauffmann A, Blommers MJ, Kazic-Legueux M, et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol Cancer Ther. 2012; 11(8):1747-57. doi: 10.1158/1535-7163.MCT-11- 1021 PMID: 22653967
27. Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, et al. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res. 2010; 16(2):530-40. doi: 10.1158/1078-0432.CCR- 09-0816 PMID: 20068094
28. Reynolds CP, Kang MH, Carol H, Lock R, Gorlick R, Kolb EA, et al. Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013; 60(5):791-8. doi: 10.1002/pbc.24301 PMID: 23002019
29. Gobin B, Huin MB, Lamoureux F, Ory B, Charrier C, Lanel R, et al. BYL719, a new alpha-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. International journal of cancer Journal international du cancer. 2014. doi: 10.1002/ijc. 29040
30. Gobin B, Battaglia S, Lanel R, Chesneau J, Amiaud J, Redini F, et al. NVP-BEZ235, a dual PI3K/ mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate. Cancer Lett. 2014; 344(2):291-8. doi: 10.1016/j.canlet.2013.11.017 PMID: 24333720
31. Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res. 2012; 18(9):2625-31. doi: 10.1158/1078-0432. CCR-12-0061 PMID: 22465830
32. Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013; 14(4):371-82. doi: 10.1016/S1470-2045(13)70049-4 PMID: 23477833
33. Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, et al. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS genetics. 2014; 10(7): e1004475. doi: 10.1371/journal.pgen.1004475 PMID: 25010205
34. Perry JA, Kiezun A, Tonzi P, Van Allen EM, Carter SL, Baca SC, et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014; 111(51):E5564-73. doi: 10.1073/pnas.1419260111 PMID: 25512523
35. Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014; 4(2):216-31. doi: 10.1158/2159- 8290.CD-13-0639 PMID: 24436047